Loading...

Cannabis Sativa

MUN:9C4
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9C4
MUN
$76M
Market Cap
  1. Home
  2. DE
  3. Household
Company description

Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
9C4 Share Price and Events
7 Day Returns
0%
MUN:9C4
-0.6%
Europe Personal Products
0.4%
DE Market
1 Year Returns
-
MUN:9C4
0.7%
Europe Personal Products
-19.5%
DE Market
9C4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cannabis Sativa (9C4) 0% 0% - - - -
Europe Personal Products -0.6% -1.4% -0.1% 0.7% 32.9% 65.2%
DE Market 0.4% -4.9% -12% -19.5% -4% 2.5%
1 Year Return vs Industry and Market
  • No trading data on 9C4.
  • No trading data on 9C4.
Price Volatility
9C4
Industry
5yr Volatility vs Market

9C4 Value

 Is Cannabis Sativa undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cannabis Sativa to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cannabis Sativa.

MUN:9C4 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for MUN:9C4
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.42
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.419 (1 + (1- 21%) (1.15%))
0.423
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.8 * 9.46%)
8.11%

Discounted Cash Flow Calculation for MUN:9C4 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cannabis Sativa is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

MUN:9C4 DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) 0.41 0.48 0.57 0.67 0.78
Source Est @ 20%, capped from 90.75% Est @ 19%, capped from 90.75% Est @ 18%, capped from 90.75% Est @ 17%, capped from 90.75% Est @ 16%, capped from 90.75%
Present Value
Discounted (@ 8.11%)
0.38 0.41 0.45 0.49 0.53
Present value of next 5 years cash flows $2.26
MUN:9C4 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $0.78 × (1 + 0.54%) ÷ (8.11% – 0.54%)
$10.32
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $10.32 ÷ (1 + 8.11%)5
$6.99
MUN:9C4 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $2.26 + $6.99
$9.25
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $9.25 / 21.73
$0.65
MUN:9C4 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in MUN:9C4 represents 1.53179x of OTCPK:CBDS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.53179x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 0.43 x 1.53179
€0.65
Value per share (EUR) From above. €0.65
Current discount Discount to share price of €5.30
= -1 x (€5.30 - €0.65) / €0.65
-713.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Cannabis Sativa is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cannabis Sativa's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cannabis Sativa's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
MUN:9C4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.26
OTCPK:CBDS Share Price ** OTCPK (2018-09-20) in USD $3.46
Europe Personal Products Industry PE Ratio Median Figure of 24 Publicly-Listed Personal Products Companies 20.31x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 16.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cannabis Sativa.

MUN:9C4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:CBDS Share Price ÷ EPS (both in USD)

= 3.46 ÷ -0.26

-13.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannabis Sativa is loss making, we can't compare its value to the Europe Personal Products industry average.
  • Cannabis Sativa is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cannabis Sativa's expected growth come at a high price?
Raw Data
MUN:9C4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Personal Products Industry PEG Ratio Median Figure of 15 Publicly-Listed Personal Products Companies 1.14x
Germany Market PEG Ratio Median Figure of 278 Publicly-Listed Companies 1.31x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cannabis Sativa, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cannabis Sativa's assets?
Raw Data
MUN:9C4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.10
OTCPK:CBDS Share Price * OTCPK (2018-09-20) in USD $3.46
Europe Personal Products Industry PB Ratio Median Figure of 41 Publicly-Listed Personal Products Companies 2.35x
Germany Market PB Ratio Median Figure of 567 Publicly-Listed Companies 1.73x
MUN:9C4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:CBDS Share Price ÷ Book Value per Share (both in USD)

= 3.46 ÷ 0.10

33.65x

* Primary Listing of Cannabis Sativa.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannabis Sativa is overvalued based on assets compared to the Europe Personal Products industry average.
X
Value checks
We assess Cannabis Sativa's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Cannabis Sativa has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

9C4 Future Performance

 How is Cannabis Sativa expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannabis Sativa has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.8%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cannabis Sativa expected to grow at an attractive rate?
  • Unable to compare Cannabis Sativa's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cannabis Sativa's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Cannabis Sativa's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
MUN:9C4 Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 6.8%
Europe Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
MUN:9C4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
MUN:9C4 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 1 -1 -5
2018-06-30 1 -1 -6
2018-03-31 0 -1 -7
2017-12-31 0 -1 -8
2017-09-30 0 -1 -7
2017-06-30 0 -1 -7
2017-03-31 0 -0 -5
2016-12-31 0 -0 -3
2016-09-30 0 -0 -5
2016-06-30 0 -0 -6
2016-03-31 0 -0 -8
2015-12-31 0 -0 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cannabis Sativa is high growth as no earnings estimate data is available.
  • Unable to determine if Cannabis Sativa is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
MUN:9C4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cannabis Sativa Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MUN:9C4 Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.26
2018-06-30 -0.27
2018-03-31 -0.32
2017-12-31 -0.38
2017-09-30 -0.38
2017-06-30 -0.36
2017-03-31 -0.26
2016-12-31 -0.18
2016-09-30 -0.27
2016-06-30 -0.36
2016-03-31 -0.47
2015-12-31 -0.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cannabis Sativa will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Cannabis Sativa's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Cannabis Sativa's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Cannabis Sativa's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cannabis Sativa's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cannabis Sativa has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

9C4 Past Performance

  How has Cannabis Sativa performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cannabis Sativa's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cannabis Sativa does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cannabis Sativa's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cannabis Sativa's 1-year growth to the Europe Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Cannabis Sativa's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cannabis Sativa Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MUN:9C4 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.60 -5.37 5.27
2018-06-30 0.62 -5.68 5.70
2018-03-31 0.41 -6.54 6.38
2017-12-31 0.32 -7.56 7.03
2017-09-30 0.13 -7.27 7.04
2017-06-30 0.01 -6.68 6.31
2017-03-31 0.03 -4.82 4.50
2016-12-31 0.03 -3.13 2.82
2016-09-30 0.03 -4.73 4.45
2016-06-30 0.03 -6.04 5.75
2016-03-31 0.01 -7.86 7.52
2015-12-31 0.01 -9.32 8.97
2015-09-30 0.01 -19.42 6.40 0.00
2015-06-30 0.01 -17.86 4.81 0.00
2015-03-31 0.01 -16.08 3.04 0.00
2014-12-31 0.01 -14.37 1.32 0.00
2014-09-30 0.00 -43.62 0.46
2013-12-31 0.00 -43.35 0.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cannabis Sativa has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cannabis Sativa has efficiently used its assets last year compared to the Europe Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cannabis Sativa improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cannabis Sativa's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cannabis Sativa has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

9C4 Health

 How is Cannabis Sativa's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cannabis Sativa's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cannabis Sativa's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Cannabis Sativa has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cannabis Sativa's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cannabis Sativa Company Filings, last reported 2 months ago.

MUN:9C4 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 4.01 0.88 0.22
2018-06-30 4.33 0.79 0.12
2018-03-31 5.50 0.79 0.07
2017-12-31 6.21 0.00 0.18
2017-09-30 8.42 0.00 0.22
2017-06-30 2.80 0.00 0.44
2017-03-31 3.42 0.00 0.89
2016-12-31 2.83 0.00 0.26
2016-09-30 3.48 0.00 0.11
2016-06-30 3.55 0.17 0.07
2016-03-31 2.74 0.00 0.05
2015-12-31 2.54 0.01 0.05
2015-09-30 4.47 0.00 0.03
2015-06-30 5.54 0.80 0.03
2015-03-31 4.62 3.56 0.02
2014-12-31 -0.28 0.00 0.03
2014-09-30 12.69 0.42 0.04
2013-12-31 -32.50 0.21 0.01
  • Cannabis Sativa's level of debt (21.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Cannabis Sativa's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Cannabis Sativa has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Cannabis Sativa has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 48.3% per year.
X
Financial health checks
We assess Cannabis Sativa's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cannabis Sativa has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

9C4 Dividends

 What is Cannabis Sativa's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cannabis Sativa dividends.
If you bought €2,000 of Cannabis Sativa shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cannabis Sativa's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cannabis Sativa's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
MUN:9C4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.6%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cannabis Sativa has not reported any payouts.
  • Unable to verify if Cannabis Sativa's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cannabis Sativa's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cannabis Sativa has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cannabis Sativa's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cannabis Sativa afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cannabis Sativa has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

9C4 Management

 What is the CEO of Cannabis Sativa's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Gravel
COMPENSATION $391,809
AGE 88
TENURE AS CEO 2.8 years
CEO Bio

Senator Mike Gravel has been the Chief Executive Officer of Cannabis Sativa, Inc., since March 29, 2016. Senator Gravel has been Chairman of the Board and Chief Executive Officer at THC Farmaceuticals, Inc. since May 15, 2015. Senator Gravel served as a U.S. Senator from Alaska from 1969 to 1981. He served as President and Chief Executive Officer of KUSH. Senator Gravel has been a Director of Cannabis Sativa, Inc. since October 01, 2014. Senator Gravel served as Director of Kush from March 2013 to July 2014. Senator Gravel sat on the Finance, Interior, Environmental and Public Works committees and chaired the Energy, Water Resources, Buildings and Grounds and Environmental Pollution subcommittees. Senator Gravel is best known for his work on the Vietnam War. He filibustered for five months which contributed to the end of the military draft. He challenged the U.S. Government by releasing the Pentagon Papers. When the Nixon administration refused to allow the New York Times to publish information on the Pentagon Papers, Senator Gravel attempted to read the entire 7,000 pages of the document into the Senate record. The Supreme Court blocked his attempt. Senator Gravel then wrote The Senator Gravel Edition, The Pentagon Papers in 1971. He received a ruling that affected the Speech and Debate Clause of the Constitution. In retirement, Senator Gravel has written two books, Jobs and More Jobs and Citizen Power. He was a Democratic and Libertarian Party candidate for President of the United States in 2008. He co-authored A Political Odyssey and The King Makers. In 2008, Senator Gravel received the Columbia University School of General Studies' first annual Isaac Asimov Lifetime Achievement Award. He was the third Speaker of the Alaska House of Representatives. He graduated from the Columbia University School of General Studies and holds four honorary doctorate degrees.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cannabis Sativa management team in years:

2.8
Average Tenure
67
Average Age
  • The tenure for the Cannabis Sativa management team is about average.
Management Team

Mike Gravel

TITLE
CEO & Director
COMPENSATION
$392K
AGE
88
TENURE
2.8 yrs

David Tobias

TITLE
President
COMPENSATION
$634K
AGE
67
TENURE
2.8 yrs

Don Lundbom

TITLE
CFO & Chief Accounting Officer
COMPENSATION
$279K
AGE
66
TENURE
1.5 yrs

Catherine Carroll

TITLE
Treasurer & Director
COMPENSATION
$363K
AGE
77
TENURE
5.4 yrs

Carolyn Merrill

TITLE
Controller
COMPENSATION
$64K
AGE
51
Board of Directors Tenure

Average tenure and age of the Cannabis Sativa board of directors in years:

4
Average Tenure
72
Average Age
  • The tenure for the Cannabis Sativa board of directors is about average.
Board of Directors

Steve Downing

TITLE
Chairman of the Board
AGE
79
TENURE
1.2 yrs

Mike Gravel

TITLE
CEO & Director
COMPENSATION
$392K
AGE
88
TENURE
4.2 yrs

David Tobias

TITLE
President
COMPENSATION
$634K
AGE
67
TENURE
5.9 yrs

Catherine Carroll

TITLE
Treasurer & Director
COMPENSATION
$363K
AGE
77
TENURE
5.4 yrs

Debby Goldsberry

TITLE
Director
AGE
51
TENURE
3.8 yrs

Trevor Reed

TITLE
Director
AGE
54
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • Cannabis Sativa insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Dec 18 Sell Donald Lundbom Individual 10. Dec 18 10. Dec 18 -3,000 €3.52 €-10,556
13. Dec 18 Sell Deborah Goldsberry Individual 12. Dec 18 12. Dec 18 -2,844 €3.45 €-9,810
11. Dec 18 Sell Sadia Barrameda Individual 04. Dec 18 04. Dec 18 -4,000 €2.93 €-11,728
11. Dec 18 Sell Sadia Barrameda Individual 13. Sep 18 10. Dec 18 -68,050 €6.41 €-287,529
01. Dec 18 Sell David Tobias Individual 27. Nov 18 30. Nov 18 -24,034 €3.53 €-78,550
13. Nov 18 Sell David Tobias Individual 06. Nov 18 13. Nov 18 -16,050 €4.52 €-68,903
13. Nov 18 Sell Donald Lundbom Individual 07. Nov 18 07. Nov 18 -3,000 €4.36 €-13,074
26. Oct 18 Sell David Tobias Individual 24. Oct 18 26. Oct 18 -8,050 €4.16 €-32,808
17. Oct 18 Sell David Tobias Individual 15. Oct 18 17. Oct 18 -27,600 €4.94 €-126,229
09. Oct 18 Sell David Tobias Individual 04. Oct 18 05. Oct 18 -3,566 €4.47 €-15,951
03. Oct 18 Sell David Tobias Individual 01. Oct 18 03. Oct 18 -45,700 €4.95 €-209,472
03. Oct 18 Sell Donald Lundbom Individual 02. Oct 18 02. Oct 18 -3,000 €4.85 €-14,558
17. Sep 18 Sell Donald Lundbom Individual 10. Sep 18 17. Sep 18 -5,000 €3.85 €-18,055
10. Sep 18 Sell Sadia Barrameda Individual 21. Aug 18 21. Aug 18 -9,000 €3.16 €-28,423
10. Sep 18 Sell Sadia Barrameda Individual 14. Jun 18 30. Aug 18 -23,218 €3.55 €-78,365
28. Aug 18 Sell Donald Lundbom Individual 21. Aug 18 21. Aug 18 -3,000 €3.47 €-10,411
20. Aug 18 Sell Donald Lundbom Individual 17. Aug 18 20. Aug 18 -20,000 €3.50 €-60,600
20. Aug 18 Sell David Tobias Individual 20. Aug 18 20. Aug 18 -19,088 €3.39 €-60,125
09. Aug 18 Sell David Tobias Individual 06. Aug 18 09. Aug 18 -7,133 €2.39 €-16,719
03. Aug 18 Sell David Tobias Individual 02. Aug 18 03. Aug 18 -8,329 €2.35 €-19,259
01. Aug 18 Sell David Tobias Individual 30. Jul 18 01. Aug 18 -5,200 €2.30 €-11,903
01. Aug 18 Sell Deborah Goldsberry Individual 01. Aug 18 01. Aug 18 -3,398 €2.27 €-7,717
27. Jul 18 Sell David Tobias Individual 26. Jul 18 27. Jul 18 -8,600 €2.39 €-20,172
25. Jul 18 Sell David Tobias Individual 24. Jul 18 25. Jul 18 -13,000 €2.45 €-30,267
18. Jul 18 Sell David Tobias Individual 17. Jul 18 18. Jul 18 -5,500 €2.69 €-14,528
12. Jul 18 Sell David Tobias Individual 09. Jul 18 09. Jul 18 -2,400 €2.93 €-7,028
22. Jun 18 Sell David Tobias Individual 20. Jun 18 21. Jun 18 -10,000 €3.49 €-34,911
08. Jun 18 Sell David Tobias Individual 07. Jun 18 08. Jun 18 -10,550 €3.57 €-37,616
08. Jun 18 Sell Deborah Goldsberry Individual 06. Jun 18 06. Jun 18 -9,828 €3.49 €-33,969
08. Jun 18 Sell Donald Lundbom Individual 07. Jun 18 07. Jun 18 -2,500 €3.59 €-8,986
06. Jun 18 Sell Sadia Barrameda Individual 13. Apr 18 22. May 18 -30,252 €4.32 €-115,173
06. Jun 18 Sell Deborah Goldsberry Individual 31. May 18 31. May 18 -2,766 €3.41 €-9,442
22. May 18 Sell Donald Lundbom Individual 18. May 18 22. May 18 -10,000 €3.73 €-37,177
22. May 18 Sell David Tobias Individual 19. May 18 22. May 18 -10,200 €3.82 €-38,610
02. May 18 Sell Donald Lundbom Individual 30. Apr 18 02. May 18 -3,955 €3.59 €-14,206
02. May 18 Sell Mike Gravel Individual 01. May 18 01. May 18 -913 €3.58 €-3,271
30. Apr 18 Sell Mike Gravel Individual 26. Apr 18 28. Apr 18 -15,753 €3.68 €-56,926
25. Apr 18 Sell Mike Gravel Individual 19. Apr 18 25. Apr 18 -57,235 €3.86 €-214,010
18. Apr 18 Sell Mike Gravel Individual 16. Apr 18 18. Apr 18 -57,515 €4.04 €-218,543
13. Apr 18 Sell Donald Lundbom Individual 11. Apr 18 12. Apr 18 -9,495 €3.30 €-30,807
20. Feb 18 Sell Sadia Barrameda Individual 08. Jan 18 20. Feb 18 -28,231 €6.65 €-156,757
16. Feb 18 Sell Donald Lundbom Individual 14. Feb 18 14. Feb 18 -2,500 €5.04 €-12,595
08. Feb 18 Sell Donald Lundbom Individual 06. Feb 18 07. Feb 18 -10,000 €4.92 €-45,587
02. Feb 18 Sell Deborah Goldsberry Individual 31. Jan 18 31. Jan 18 -5,000 €4.82 €-24,117
24. Jan 18 Sell Donald Lundbom Individual 18. Jan 18 23. Jan 18 -5,000 €5.70 €-27,116
18. Jan 18 Sell Trevor Reed Individual 16. Jan 18 16. Jan 18 -37,322 €5.56 €-207,366
12. Jan 18 Sell Trevor Reed Individual 09. Jan 18 09. Jan 18 -2,678 €7.00 €-18,757
10. Jan 18 Sell David Tobias Individual 08. Jan 18 08. Jan 18 -17,914 €6.26 €-112,173
06. Jan 18 Sell David Tobias Individual 03. Jan 18 05. Jan 18 -115,000 €7.80 €-719,591
11. Jan 18 Sell Stephen Downing Individual 05. Jan 18 08. Jan 18 -25,000 €6.09 €-148,796
10. Jan 18 Sell Catherine Carroll Individual 08. Jan 18 10. Jan 18 -42,700 €6.85 €-283,873
09. Jan 18 Sell Trevor Reed Individual 21. Dec 17 21. Dec 17 -7,000 €4.26 €-29,815
09. Jan 18 Sell Trevor Reed Individual 02. Jan 18 03. Jan 18 -23,000 €7.42 €-166,730
06. Jan 18 Sell Donald Lundbom Individual 02. Jan 18 03. Jan 18 -6,000 €7.50 €-40,630
06. Jan 18 Sell Catherine Carroll Individual 04. Jan 18 04. Jan 18 -10,000 €6.22 €-62,166
06. Jan 18 Sell Sadia Barrameda Individual 05. Jul 17 03. Jan 18 -63,486 €7.47 €-334,400
29. Dec 17 Sell Donald Lundbom Individual 26. Dec 17 28. Dec 17 -5,000 €5.99 €-26,340
20. Dec 17 Sell Donald Lundbom Individual 18. Dec 17 19. Dec 17 -3,758 €4.29 €-16,001
X
Management checks
We assess Cannabis Sativa's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cannabis Sativa has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

9C4 News

External News
Loading...
Simply Wall St News

9C4 Company Info

Map
Description

Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally. The company offers Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC; Face Garden, an antioxidant moisturizing cream for the face; Body Garden, a moisturizing body lotion; and Lip Garden, an emollient balm. It also offers Wild Earth Naturals and hi branded men's and women's fashion tee shirts and sweatshirts, as well as caps and coffee mugs through Website, wildearthnaturals.com. In addition, the company operates iBudtender, an online portal that offers information and patient reviews on marijuana dispensaries, cannabis businesses, marijuana strains, edibles, concentrates, and products; and PrestoCorp, an online telemedicine platform providing access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology. Cannabis Sativa, Inc. is based in Mesquite, Nevada.

Details
Name: Cannabis Sativa, Inc.
9C4
Exchange: MUN
Founded:
$66,923,745
21,733,428
Website: http://www.cannabissativainc.com
Address: Cannabis Sativa, Inc.
1646 West Pioneer Boulevard,
Suite 120,
Mesquite,
Nevada, 89027,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CBDS Common Stock Pink Sheets LLC US USD 14. Jul 2013
MUN 9C4 Common Stock Boerse Muenchen DE EUR 14. Jul 2013
Number of employees
Current staff
Staff numbers
6
Cannabis Sativa employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/18 22:49
End of day share price update: 2018/09/20 00:00
Last earnings filing: 2018/11/14
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.